九安醫療(002432.SZ):已收到美國ACC支付9113.74萬人份iHealth試劑盒產品貨款共計4.65億美元
格隆匯2月17日丨九安醫療(002432.SZ)公佈,公司子公司iHealth Labs Inc(簡稱“美國子公司”)與美國ACC(美國陸軍合約管理指揮部)代表美國HHS(美國衞生與公眾服務部)就iHealth新冠抗原家用自測OTC試劑盒產品(簡稱“iHealth試劑盒”)於當地時間2022年1月13日簽訂了《採購合同》,向其銷售2.5億人份iHealth試劑盒產品,合同價税合計金額為12.75億美元(含運費),約合人民幣81.02億元。
根據上述合同主要內容中的交貨安排,截至美國當地時間2022年2月15日,公司美國子公司已經就iHealth試劑盒產品向合同對手方交貨共計約1.77億人份,截至當地時間2022年2月15日,美國ACC再陸續向公司美國子公司就約6996.94萬人份試劑盒產品支付貨款共計約3.57億美元,約合人民幣22.65億元。
截至當地時間2022年2月15日,美國ACC已經累計向公司美國子公司就約9113.74萬人份試劑盒產品支付貨款約4.65億美元,上述貨款已於美國時間2月16日全部到賬,約合人民幣29.50億元。上述情況符合合同規定的交貨和付款安排,該合同正在履行過程中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.